Search research articles
Contact Us
Filters
Showing results (31-40 of 97) with videos related to
Page
of 10
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
November 5, 2022
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study
Anthony R Mato, Lisa M Hess, Yongmei Chen, et al.
Haematologica
|
April 21, 2022
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
Anthony R Mato, Boxiong Tang, Soraya Azmi, et al.
Cancer
|
October 15, 2013
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas
Tahamtan Ahmadi, Elise A Chong, Amanda Gordon, et al.
Cancer Biology & Therapy
|
May 16, 2019
Management of giant cell hepatitis associated with chronic lymphocytic leukemia - a case series and review of the literature
Joanna M Rhodes, Stephen J Schuster, Emma E Furth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2015
Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
Elise A Chong, Tahamtan Ahmadi, Nicole A Aqui, et al.
Cancer Biology & Therapy
|
December 28, 2017
Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia
Anthony R Mato, Suparna Clasen, Peter Pickens, et al.
Blood Advances
|
May 10, 2023
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
Lindsey E Roeker, Maral DerSarkissian, Kellie Ryan, et al.
Future Oncology (London, England)
|
September 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Christine E Ryan, Matthew S Davids, Richard Hermann, et al.
Investigational New Drugs
|
June 15, 2014
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
Ajay K Gopal, Stefano R Tarantolo, Naresh Bellam, et al.
Critical Reviews in Oncology/Hematology
|
May 6, 2022
Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
Sarah Nocco, Tyler M Andriano, Arpita Bose, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 97) with videos related to
Sort By:
Page
of 10
Clinical Lymphoma, Myeloma & Leukemia
|
November 5, 2022
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study
Anthony R Mato, Lisa M Hess, Yongmei Chen, et al.
Haematologica
|
April 21, 2022
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
Anthony R Mato, Boxiong Tang, Soraya Azmi, et al.
Cancer
|
October 15, 2013
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas
Tahamtan Ahmadi, Elise A Chong, Amanda Gordon, et al.
Cancer Biology & Therapy
|
May 16, 2019
Management of giant cell hepatitis associated with chronic lymphocytic leukemia - a case series and review of the literature
Joanna M Rhodes, Stephen J Schuster, Emma E Furth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2015
Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
Elise A Chong, Tahamtan Ahmadi, Nicole A Aqui, et al.
Cancer Biology & Therapy
|
December 28, 2017
Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia
Anthony R Mato, Suparna Clasen, Peter Pickens, et al.
Blood Advances
|
May 10, 2023
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
Lindsey E Roeker, Maral DerSarkissian, Kellie Ryan, et al.
Future Oncology (London, England)
|
September 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Christine E Ryan, Matthew S Davids, Richard Hermann, et al.
Investigational New Drugs
|
June 15, 2014
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
Ajay K Gopal, Stefano R Tarantolo, Naresh Bellam, et al.
Critical Reviews in Oncology/Hematology
|
May 6, 2022
Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
Sarah Nocco, Tyler M Andriano, Arpita Bose, et al.
Page
of 10